Neurocrine Biosciences Executive Compensation Filing
Ticker: NBIX · Form: DEF 14A · Filed: Apr 9, 2025 · CIK: 914475
| Field | Detail |
|---|---|
| Company | Neurocrine Biosciences Inc (NBIX) |
| Form Type | DEF 14A |
| Filed Date | Apr 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, sec-filing
Related Tickers: NBIX
TL;DR
NBIX proxy statement out, details exec pay for 2024. Gorman & Gano compensation info included.
AI Summary
Neurocrine Biosciences Inc. filed a DEF 14A on April 9, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. Key individuals like Kevin C. Gorman, Ph.D., and Kyle W. Gano, Ph.D., are listed with compensation details for various periods, including 2024, 2023, 2022, 2021, and 2020. The filing also includes information on equity awards granted and outstanding.
Why It Matters
This filing provides transparency into how Neurocrine Biosciences compensates its top executives, which can influence investor decisions and employee morale.
Risk Assessment
Risk Level: low — This is a routine proxy statement filing that details executive compensation and does not introduce new material risks.
Key Numbers
- 2024 — Fiscal Year (Primary year for executive compensation data reported)
- 2023 — Fiscal Year (Prior year executive compensation data reported)
- 2022 — Fiscal Year (Prior year executive compensation data reported)
- 2021 — Fiscal Year (Prior year executive compensation data reported)
- 2020 — Fiscal Year (Prior year executive compensation data reported)
Key Players & Entities
- Neurocrine Biosciences Inc. (company) — Filer of the DEF 14A
- Kevin C. Gorman, Ph.D. (person) — Member of the Board, executive compensation details provided
- Kyle W. Gano, Ph.D. (person) — Member of the Board, executive compensation details provided
- April 9, 2025 (date) — Filing date of the DEF 14A
- December 31, 2024 (date) — Fiscal year end for compensation reporting
FAQ
What is the filing type and date?
The filing type is DEF 14A, filed on April 9, 2025.
Which company filed this document?
Neurocrine Biosciences Inc. filed this document.
What is the primary fiscal year covered by the compensation details?
The primary fiscal year covered is 2024, with comparative data for 2023, 2022, 2021, and 2020.
Who are some of the key individuals mentioned in relation to compensation?
Kevin C. Gorman, Ph.D., and Kyle W. Gano, Ph.D., are key individuals for whom compensation details are provided.
What type of information is included regarding equity awards?
The filing includes information on equity awards granted in the covered year, outstanding and unvested equity awards, and changes in the fair value of outstanding equity awards.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 9, 2025 by Kevin C. Gorman, Ph.D. regarding NEUROCRINE BIOSCIENCES INC (NBIX).